GeoVax Labs Inc. (NASDAQ:GOVX) shares traded 18.35% higher at $0.89 on Wall Street last session.
In accordance with the data, 3 analysts cover GeoVax Labs Inc. (NASDAQ:GOVX). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $8.00 and a low of $3.00, we find $6.00. Given the previous closing price of $0.75, this indicates a potential upside of 700.0 percent. GOVX stock price is now 22.85% away from the 50-day moving average and -23.09% away from the 200-day moving average. The market capitalization of the company currently stands at $19.80M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
It has been rated a hold by 0 analysts and a buy by 3. Brokers who have rated the stock have averaged $5.67 as their price target over the next twelve months.
With the price target of $8, Maxim Group recently initiated with Buy rating for GeoVax Labs Inc. (NASDAQ: GOVX)..
In other news, CHASE RANDAL D, Director bought 10,000 shares of the company’s stock on Sep 21. The stock was bought for $11,000 at an average price of $1.10. Upon completion of the transaction, the Director now directly owns 36,613 shares in the company, valued at $32585.57. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 01, VP, Business Development Sharkey John W. bought 1,000 shares of the business’s stock. A total of $820 was incurred on buying the stock at an average price of $0.82. This leaves the insider owning 2,860 shares of the company worth $2545.4. A total of 0.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in GOVX stock. A new stake in GeoVax Labs Inc. shares was purchased by HIDDEN LAKE ASSET MANAGEMENT LP during the first quarter worth $299,000. SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC invested $13,000 in shares of GOVX during the first quarter. In the first quarter, HRT FINANCIAL LP acquired a new stake in GeoVax Labs Inc. valued at approximately $10,000. JANE STREET GROUP, LLC acquired a new stake in GOVX for approximately $10,000. ADVISOR GROUP HOLDINGS, INC. purchased a new stake in GOVX valued at around $4,000 in the second quarter. In total, there are 19 active investors with 11.80% ownership of the company’s stock.
GeoVax Labs Inc. (NASDAQ: GOVX) opened at $0.7424 on Friday. During the past 12 months, GeoVax Labs Inc. has had a low of $0.53 and a high of $4.30. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 7.50, and a quick ratio of 7.50. The fifty day moving average price for GOVX is $0.7242 and a two-hundred day moving average price translates $1.1550 for the stock.
The latest earnings results from GeoVax Labs Inc. (NASDAQ: GOVX) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.18, beating analysts’ expectations of -$0.32 by 0.14. This compares to -$0.31 EPS in the same period last year.
GeoVax Labs Inc.(GOVX) Company Profile
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
